Loading
Life sciences · Journal article
BMC Cancer · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
PD-1 blockade benefits MSI-H/dMMR tumors after prior therapy. Its efficacy as first-line treatment for pMMR/MSS in locally advanced rectal cancer remains unclear. We retrospectively analyzed 84 locally advanced rectal cancer (LARC) patients undergoing total mesorectal excision (TME) (2021–2026). All received neoadjuvant chemoradiotherapy (nCRT) (50.4 Gy, concurrent capecitabine, oxaliplatin plus capecitabine (XELOX)). Patients were divided into Control ( n = 59, nCRT alone) and Combination ( n = 25, nCRT plus PD − 1 inhibitor) groups. Baseline characteristics were balanced ( P > 0.05). The Combination group showed a more favorable TRG distribution than the Control group (Mann-Whitney U test, P = 0.049), with higher pCR rates (32.0% [8/25] vs. 11.9% [7/59], P = 0.041) and no TRG 3 cases (0.0% vs. 8.5%). Sphincter preservation was numerically improved (Dixon rate 84.0% vs. 64.4%, P = 0.116). The combination arm also demonstrated rapid, uniform suppression of serum CEA and CA19-9. Given the retrospective design and limited sample size, these findings should be regarded as preliminary. Adding PD-1 inhibitors to nCRT was associated with higher pCR rates and a more favorable TRG distribution. Sphincter preservation showed a favorable numerical trend (Dixon rate 84.0% vs. 64.4%, P = 0.116). These preliminary results require validation in larger cohorts before informing clinical practice.